- Home
- LEGT vs OMER Comparison
LEGT vs OMER Comparison
Compare LEGT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- OMER
- Stock Information
- Founded
- LEGT 2023
- OMER 1994
- Country
- LEGT United States
- OMER United States
- Employees
- LEGT N/A
- OMER N/A
- Industry
- LEGT
- OMER Biotechnology: Pharmaceutical Preparations
- Sector
- LEGT
- OMER Health Care
- Exchange
- LEGT Nasdaq
- OMER Nasdaq
- Market Cap
- LEGT 277.1M
- OMER 274.3M
- IPO Year
- LEGT 2024
- OMER 2009
- Fundamental
- Price
- LEGT $10.88
- OMER $8.11
- Analyst Decision
- LEGT
- OMER Strong Buy
- Analyst Count
- LEGT 0
- OMER 6
- Target Price
- LEGT N/A
- OMER $27.50
- AVG Volume (30 Days)
- LEGT 3.8K
- OMER 8.0M
- Earning Date
- LEGT 01-01-0001
- OMER 11-12-2025
- Dividend Yield
- LEGT N/A
- OMER N/A
- EPS Growth
- LEGT N/A
- OMER N/A
- EPS
- LEGT 0.33
- OMER N/A
- Revenue
- LEGT N/A
- OMER N/A
- Revenue This Year
- LEGT N/A
- OMER N/A
- Revenue Next Year
- LEGT N/A
- OMER N/A
- P/E Ratio
- LEGT $33.15
- OMER N/A
- Revenue Growth
- LEGT N/A
- OMER N/A
- 52 Week Low
- LEGT $10.20
- OMER $2.95
- 52 Week High
- LEGT $10.95
- OMER $13.60
- Technical
- Relative Strength Index (RSI)
- LEGT 66.26
- OMER 66.03
- Support Level
- LEGT $10.79
- OMER $4.06
- Resistance Level
- LEGT $10.95
- OMER $12.10
- Average True Range (ATR)
- LEGT 0.03
- OMER 0.60
- MACD
- LEGT 0.01
- OMER 0.53
- Stochastic Oscillator
- LEGT 66.67
- OMER 49.35
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.